Abstract: A battery powered automatic wrench including a wrench assembly, an electric assembly, and a transmission assembly. The wrench assembly includes a handle that is removably attached to a wrench head. The electrical assembly includes a motor that can be regulated using a display and buttons disposed on the handle. A user can select a predetermined speed and torque for the motor to deliver it. The electrical assembly further includes a battery to power the motor and the display. The transmission assembly includes gears, spindles, a coupler, and toothed belt to transmit motion from the motor to a driving element partially housed by the wrench head. The driving element can receive different sized sockets that are suitable to fasten or loosen nuts, bolts, or the like.

Abstract: A biomedical electrode for electrically contacting a user's skin includes a carrier layer, a backing layer, an electrical lead, a conductive member, and a gel contact member. The backing layer is disposed on the carrier layer. The electrical lead is positioned at least in part below the carrier layer. The conductive member is coupled to the electrical lead. The gel contact member is electrically coupled to the conductive member for directly contacting the user's skin. The gel contact member is electrically conductive. The gel contact member includes a gel combined with an anti-microbial agent.

Abstract: A biomedical electrode for electrically contacting a user's skin includes a carrier layer, a backing layer, an electrical lead, a conductive member, and a gel contact member. The backing layer is disposed on the carrier layer. The electrical lead is positioned at least in part below the carrier layer. The conductive member is coupled to the electrical lead. The gel contact member is electrically coupled to the conductive member for directly contacting the user's skin. The gel contact member is electrically conductive. The gel contact member includes a gel combined with an anti-microbial agent.

Abstract: A biomedical electrode for electrically contacting a user’s skin includes a carrier layer, a backing layer, an electrical lead, a conductive member, and a gel contact member. The backing layer is disposed on the carrier layer. The electrical lead is positioned at least in part below the carrier layer. The conductive member is coupled to the electrical lead. The gel contact member is electrically coupled to the conductive member for directly contacting the user’s skin. The gel contact member is electrically conductive.

Abstract: The present invention is a pyrotechnic time delay system that is improved over prior-art designs. Specifically, the system described herein comprises at least one delay element. The delay element or delay elements each have an input charge, a delay composition, and an output charge. Both the input charge and the output charge are igniter compositions and are comprised of the same components despite having different functional goals. The input charge and output charge compositions preferably contain titanium, manganese dioxide, and polytetrafluoroethylene. The delay composition may be modified from current formulations to include manganese and manganese dioxide, or tungsten and manganese dioxide. The system disclosed herein may be comprised of one delay element, or it may be modular wherein multiple delay elements are connected in series.

Abstract: The present invention is a pyrotechnic time delay system that is improved over prior-art designs. Specifically, the system described herein comprises at least one delay element. The delay element or delay elements each have an input charge, a delay composition, and an output charge. Both the input charge and the output charge are igniter compositions and are comprised of the same components despite having different functional goals. The input charge and output charge compositions preferably contain titanium, manganese dioxide, and polytetrafluoroethylene. The delay composition may be modified from current formulations to include manganese and manganese dioxide, or tungsten and manganese dioxide. The system disclosed herein may be comprised of one delay element, or it may be modular wherein multiple delay elements are connected in series.

Abstract: A biomedical electrode for electrically contacting a user's skin includes a carrier layer, a backing layer, an electrical lead, a conductive member, and a gel contact member. The backing layer is disposed on the carrier layer. The electrical lead is positioned at least in part below the carrier layer. The conductive member is coupled to the electrical lead. The gel contact member is electrically coupled to the conductive member for directly contacting the user's skin. The gel contact member is electrically conductive.

Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

Abstract: A hand-operated stick device includes a gripping portion, a working member and an elongated shaft with opposite ends connecting the gripping portion and the working member. The shaft has a wall thickness and at least three ribs projected from an inner side of the shaft. The ribs extend from an end of the shaft adjacent to the gripping portion to the other end adjacent to the working member. The ribs have a width and a height both of which are greater than or equal to the wall thickness. Therefore, it may increase the strength of structure and provide a safe use.

Abstract: A rotary dumbbell of the present invention includes a handle, and two pairs of wheels and weight devices pivoted on opposite ends of the handle for rotation. Each of the wheels has a center pivoted on the handle and is unadjustable in a radial direction thereof that the wheels centrally rotate. Each of the weight devices is adjustable in a radial direction thereof that the weight devices may eccentrically rotate. The dumbbell further includes two pairs of covers to hold the weight devices and the wheels respectively. Therefore, user may get an extra loading because of the eccentric rotation of the weight devices when he/she shakes the dumbbell. The dumbbell may be used as a roller to train abdominal muscles while the wheels serve the function of rollers.

Abstract: The discovery that apolipoprotein B exhibits spectral features in the mid IR spectrum that make it identifiable within blood serum leads to the invented use of a statistical correlation between a concentration of apolipoprotein-B (apoB) in a sample of blood serum and infrared spectral features of the blood serum sample to produce a test for apoB. A method for providing such a test, and tests produced by the method are taught.

Abstract: A number of reagent-free infrared spectroscopic diagnostic and analytical methods have been established previously, making use of dry biofluid films. For example, this approach has successfully measured high concentration analytes of serum and urine. However, a number of low concentration diagnostically relevant analytes presently elude detection by infrared spectroscopy. This is due in part to their relatively low concentration and in part to spectral interference by other strongly absorbing constituents. The applicability of the technique would be broadened substantially if it were possible to separate and concentrate, lower concentration analytes, e.g. serum creatinine and urine proteins, from the obscuring presence of relatively high concentration compounds. The invention disclosed achieves this is through microfluidic sample preconditioning based upon laminar fluid diffusion interfaces.

Abstract: The discovery that apolipoprotein B exhibits spectral features in the mid IR spectrum that make it identifiable within blood serum leads to the invented use of a statistical correlation between a concentration of apolipoprotein-B (apoB) in a sample of blood serum and infrared spectral features of the blood serum sample to produce a test for apoB. A method for providing such a test, and tests produced by the method are taught.

Abstract: Compounds of Formula (I) and Formula (II) (where variables R1, R2, R4, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Abstract: Compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, D, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, pharmaceutical compositions comprising these compounds, use of these compounds and compositions to prevent or treat diseases involving CGRP.

Abstract: A mesh sponge is formed as a batting of multiple layers of a tubular mesh material defining a pocket. The pocket may house a cleaning aid article, for example, a bar of soap or a structural form. Liquid soap may be used in conjunction with the mesh sponge and structural form, which provides a solid feel to the user. The pocket in the mesh sponge may house a bladder that is filled with liquid soap. The bladder may be porous or contain one or more valved openings to facilitate the excretion or dispensing of the liquid soap upon squeezing of the bladder by a user.

Abstract: The present invention is directed to compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.